Lenzilumab missed its primary endpoint in the ACTIV-5/BET-B trial, conducted by the NIH’s National Institute of Allergy and Infectious Diseases. The study compared whether lenzilumab plus Gilead Sciences’ Veklury® (remdesivir) was more effective than placebo plus remdesivir in hospitalized COVID-19 patients. Lenzilumab plus remdesivir did not achieve statistical significance on the primary endpoint, the proportion of patients with baseline CRP . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post StockWatch: Humanigen Wilts after COVID-19 Antibody Fails NIH Trial appeared first on GEN – Genetic Engineering and Biotechnology News.
